Rani Therapeutics
Yahoo Finance • last year
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results
- Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of RaniPill® HC to be Phase 1 ready - - Expansion of... Full story
Yahoo Finance • last year
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study
– Daily administration for 60 days was well-tolerated with no treatment-related adverse events – – Preclinical data support the safety and tolerability of RaniPill® capsule for subsequent clinical studies – SAN JOSE, Calif., Oct. 25, 20... Full story
Yahoo Finance • last year
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
- RaniPill®HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – - RaniPill® HC shortlisted as a finalist b... Full story
Yahoo Finance • last year
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today anno... Full story
Yahoo Finance • last year
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,... Full story
Yahoo Finance • last year
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
-Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate -Rani will continue preclinical testing to confirm preliminary reliability rat... Full story
Yahoo Finance • last year
Rani Therapeutics to Participate in September Investor Conferences
SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ann... Full story
Yahoo Finance • last year
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endo... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics’ Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference
SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ann... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - - Received preliminary feedback from FDA on RT-1... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ann... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update
- Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of Phase 2 study of RT-102 in osteoporosis -... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study
- RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill™ GO delivered PTH to subjects with a 91% success... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colit... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics to Present at the Stifel Healthcare Conference
SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today anno... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update
- Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis - - RT-102 Phase 1 repeat-do... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ann... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock
SAN JOSE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, tod... Full story
Yahoo Finance • 2 years ago
Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock
SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it intend... Full story
